OKUR – onkure therapeutics, inc. - class a (US:NASDAQ)
Stock Stats
News
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Ka Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies [Yahoo! Finance]
OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Ka Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
OnKure Therapeutics (OKUR) had its price target lowered by HC Wainwright from $34.00 to $27.00. They now have a "buy" rating on the stock.
OnKure Therapeutics (OKUR) was upgraded by Wall Street Zen from "sell
OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Form 3 OnKure Therapeutics, For: Mar 31 Filed by: Blavatnik Len
Form SCHEDULE 13D OnKure Therapeutics, Filed by: AI Biotechnology LLC
Form SCHEDULE 13G OnKure Therapeutics, Filed by: StepStone Group LP
Form SCHEDULE 13G OnKure Therapeutics, Filed by: Trails Edge Capital Partners, LP
Form SCHEDULE 13G OnKure Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.